结合MRI与超声图像的人工智能模型MRUSuNet在前列腺癌检测中优于放射科医生MRI判读
本研究开发了MRUSuNet模型,以MRI和经直肠超声(TRUS)为输入,在前列腺癌TRUS图像上检测并定位临床显著癌的三维空间体积。模型开发使用两个MRI-TRUS融合穿刺队列(3000例),独立验证与放射科医生比较使用一个根治性前列腺切除队列(110例),另保留1700例独立病例比较单模态模型。MRUSuNet的敏感度和病灶Dice评分显著优于仅MRI和仅TRUS模型,与放射科医生相比特异度和Dice评分显著更高、敏感度无统计学差异。
要点
- MRUSuNet敏感度0.80、病灶Dice评分0.42,优于仅MRI模型(0.73、0.30)和仅TRUS模型(0.49、0.27)。
- 与放射科医生相比,MRUSuNet特异度0.88 vs 0.78(P=0.004)、Dice评分0.32 vs 0.27(P=0.048),敏感度0.79无统计学差异。
- 多模态AI模型可改善TRUS图像上临床显著前列腺癌的定位,支持作为MRI-TRUS融合工作流程的辅助工具进一步研究。
核心结论
- 结合MRI与TRUS的多模态AI模型MRUSuNet在TRUS图像上定位临床显著前列腺癌优于单模态模型,并较放射科医生MRI判读表现出更高特异度和病灶Dice评分。
研究设计与样本
- 模型开发使用两个MRI-TRUS融合穿刺队列共3000例患者,独立验证及与放射科医生比较使用一个根治性前列腺切除队列110例。
- 另保留1700例独立病例用于比较MRUSuNet与仅MRI模型和仅TRUS模型。
- 以穿刺队列的靶向穿刺病理和根治性前列腺切除队列的全mount前列腺切除病理为参考标准,计算敏感度和病灶级Dice相似度评分。
主要发现
- MRUSuNet在所有测试队列中敏感度0.80、病灶Dice评分0.42,显著优于仅MRI模型(敏感度0.73,P=0.033;Dice评分0.30,P<0.001)。
- MRUSuNet显著优于仅TRUS模型(敏感度0.49,P<0.001;Dice评分0.27,P<0.001)。
- 在根治性前列腺切除队列中,MRUSuNet较放射科医生特异度显著更高(0.88 vs 0.78;P=0.004),病灶Dice评分显著更高(0.32 vs 0.27;P=0.048)。
- MRUSuNet与放射科医生敏感度(0.79)无统计学差异(P=1.000)。
临床怎么用
- MRUSuNet可作为MRI-TRUS融合穿刺工作流程的辅助工具,改善TRUS图像上临床显著前列腺癌的可视化与定位。
局限性
- 研究为回顾性多队列设计,模型开发与验证队列来源不同,需进一步前瞻性研究验证其临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives To develop the magnetic resonance imaging (MRI)-UltraSound UNet (MRUSuNet), a model that uses both MRI and transrectal ultrasonography (TRUS) as input to detect and localise the three-dimensional spatial volume of clinically significant prostate cancer on TRUS images to allow better visualisation of cancer in the TRUS space. Patients and Methods Pre-biopsy MRI is increasingly used to target suspicious prostate lesions. The lesions identified by radiologists are mapped onto TRUS images to enable real-time targeting during the biopsy. Yet, the misalignment of MRI and TRUS results in sampling errors, and in some cases even missing the clinically significant cancers. This study included two MRI-TRUS fusion biopsy cohorts (3000 patients) for model development, and one radical prostatectomy cohort (110 patients) used for independent validation and for the comparison with radiologist interpretation. A total of 1700 independent cases were reserved to compare the MRUSuNet with single-modality MRI-only and TRUS-only models. Sensitivity and lesion-level Dice similarity scores were computed using targeted biopsy pathology as the reference standard in the biopsy cohorts and whole-mount prostatectomy pathology in the radical prostatectomy cohort. Result The MRUSuNet achieved significantly superior sensitivity (0.80) and lesion Dice score (0.42) across all test cohorts compared to the MRI-only model (sensitivity: 0.73, P = 0.033; Dice score: 0.30, P < 0.001) and the TRUS-only model (sensitivity: 0.49, P < 0.001; Dice score: 0.27, P < 0.001). Compared to radiologists in the prostatectomy cohort, the MRUSuNet showed significantly higher specificity (0.88 vs 0.78; P = 0.004) and lesion Dice score (0.32 vs 0.27; P = 0.048), with no observed statistical difference in sensitivity (0.79; P = 1.000). Conclusion Our findings demonstrate the potential of combining MRI and TRUS in a multimodal artificial intelligence (AI) model to improve localisation of clinically significant prostate cancer on TRUS images relative to single-modality models. These findings support further study of such multimodal AI models as an adjunct to MRI-TRUS fusion workflows.
引用
- BJU International:An artificial intelligence model combining MRI and ultrasound images (MRUSuNet) for prostate cancer detection outperforms radiologist MRI interpretation
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。